FindMyKOL
Clinical trialNCT00305812CompletedPhase 2Interventional

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

SponsorNCIC Clinical Trials GroupEnrollment51Multiple Myeloma and Plasma Cell Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with melphalan may kill more cancer cells. PURPOSE: This randomized phase II trial is studying the side effects and best dose of lenalidomide when given together with melphalan and to see how well they work in treating patients with multiple myeloma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Tom Baker Cancer Centre - Calgary

    Calgary, Alberta, Canada

  • Cross Cancer Institute at University of Alberta

    Edmonton, Alberta, Canada

  • British Columbia Cancer Agency - Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Moncton Hospital

    Moncton, New Brunswick, Canada

  • Nova Scotia Cancer Centre

    Halifax, Nova Scotia, Canada

  • Margaret and Charles Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • London Regional Cancer Program at London Health Sciences Centre

    London, Ontario, Canada

  • Algoma District Cancer Program at Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada

  • Humber River Regional Hospital - Weston

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Hopital Charles Lemoyne

    Greenfield Park, Quebec, Canada

  • Hopital Notre-Dame Du Chum

    Montreal, Quebec, Canada

  • Mcgill Cancer Centre at Mcgill University

    Montreal, Quebec, Canada

  • Allan Blair Cancer Centre at Pasqua Hospital

    Regina, Saskatchewan, Canada

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Mar 2006
Primary completion
30 Jun 2008
Completion
30 Jun 2008
Last update posted
4 Aug 2023
Registered enrollment
51
Registry id
NCT00305812

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.